Faecal Microbiota Transplantation After Allogeneic Stem Cell Transplantation (TMF-Allo)

Faecal Microbiota Transplantation for Prevention of Graft-versus-host Sisease After Allogeneic Stem Cell Transplantation for Haematological Malignancies

The aim of this study is to assess the Fecal Microbiota Transplantation (FMT) efficacy in the prevention of allogeneic hematopoietic stem cell transplantation (allo-HSCT) complications and particularly Graft versus Host Disease (GvHD).

The hypothesis of this study is that allogeneic FMT may improve outcomes of these patients.

Study Overview

• Status: Recruiting
• Conditions: Lymphoma, Non-Hodgkin; Myelodysplastic Syndromes; Hodgkin Lymphoma; Chronic Lymphocytic Leukemia; Myeloma; Acute Leukemia in Remission; Myeloproliferative Syndrome
• Intervention / Treatment: Drug: Fecal Microbiota Transplantation

Detailed Description

The TMF-Allo study is a prospective, open-label, multi-center, parallel, randomized phase II clinical trial comparing a group patients with FMT and a control group of patients without FMT.

The main objective of this study is to assess the effect of allogeneic FMT versus no treatment on Graft-versus-host disease and Relapse-Free Survival (GRFS) at one year in adult patients treating with myelo-ablative allo-HSCT for haematologic malignancy.

The secondary objectives are to evaluate :

• Overall survival, progression-free survival at 1 and 2 years,
• The haematological evolution,
• The evolution of infections,
• The tolerance and safety of the TMF carried out in post-transplant,
• The evolution of the composition and diversity of the microbiota in allograft patients receiving TMF or not.

• Study Type: Interventional
• Enrollment (Anticipated): 150
• Phase: Phase 2

Contacts and Locations

Study Locations

• France
  • Amiens, France
    • Not yet recruiting
    • Service d'Hématologie Clinique et Thérapie Cellulaire CHU Amiens Picardie - Site Sud
    • Contact: Magalie Magalie, MD
    • Principal Investigator: Magalie Magalie, MD
  • Angers, France
    • Not yet recruiting
    • Service Maladies du sang CHU Angers
    • Contact: Sylvie François, MD
    • Principal Investigator: Sylvie François, MD
  • Besançon, France
    • Not yet recruiting
    • Hématologie clinique CHU Besançon
    • Contact: Etienne Daguindau, MD
    • Principal Investigator: Etienne Daguindau, MD
  • Clermont-Ferrand, France
    • Recruiting
    • Plateforme d'Investigation Clinique / Centre d'Investigation Clinique - Inserm 1405, CHU Gabriel Montpied Clermont-Ferrand
    • Contact: Christian Dualé, MD, PhD
    • Principal Investigator: Christian Dualé, MD, PhD
  • Clermont-Ferrand, France
    • Not yet recruiting
    • Service de thérapie Cellulaire et d'Hématologie Clinique Adulte CHU Estaing - Clermont-Ferrand
    • Sub-Investigator: Aurélie Ravinet, MD
    • Contact: Jacques-Olivier Bay, MD, PhD
    • Principal Investigator: Jacques-Olivier Bay, MD, PhD
  • Grenoble, France
    • Not yet recruiting
    • Service hématologie CHU Grenoble
    • Contact: Claude-Eric Bulabois, MD
    • Principal Investigator: Claude-Eric Bulabois, MD
  • Lille, France
    • Not yet recruiting
    • Service des Maladies du sang Hôpital HURIEZ, CHRU de Lille
    • Contact: David Beauvais, MD
    • Principal Investigator: David Beauvais, MD
  • Limoges, France
    • Not yet recruiting
    • Service de thérapie cellulaire et l'hématologie clinique adulte CHU Limoges
    • Contact: Pascal TURLURE, MD
    • Principal Investigator: Pascal TURLURE, MD
  • Lyon, France
    • Not yet recruiting
    • Service d'Hématologie Centre Hospitalier Lyon Sud
    • Contact: Marie-Virginie Larcher, MD
    • Principal Investigator: Marie-Virginie Larcher, MD
  • Nancy, France
    • Not yet recruiting
    • Service d'Hématologie et de Médecine interne Hôpital Brabois CHRU Nancy
    • Contact: Marie-Therese Rubio, MD
    • Principal Investigator: Marie-Therese Rubio, MD
  • Nantes, France
    • Not yet recruiting
    • Service d'Hématologie Clinique CHU Nantes
    • Contact: Patrice Chevallier, MD
  • Nice, France
    • Not yet recruiting
    • Service d'hématologie clinique, département de greffe de moelle CHU Nice
    • Contact: Michel Loschi, MD
    • Principal Investigator: Michel Loschi, MD
  • Paris, France
    • Not yet recruiting
    • Service d'Hématologie Adultes Hôpital Necker
    • Contact: Ambroise MARCAIS, MD
    • Principal Investigator: Ambroise Marçais, MD
  • Paris, France
    • Not yet recruiting
    • Service d'Hématologie clinique Hôpital Pitié-Salpêtrière
    • Contact: Stéphanie Nguyen, MD, PhD
    • Principal Investigator: Stéphanie Nguyen, MD, PhD
  • Paris, France
    • Not yet recruiting
    • Service d'hématologie greffe Hôpital St Louis
    • Contact: Marie Robin, MD
  • Pessac, France
    • Not yet recruiting
    • Hématologie clinique et thérapie cellulaire Hôpital Haut-Lévèque
    • Contact: Carmen Botella Garcia, MD
    • Principal Investigator: Carmen Botella Garcia, MD
  • Poitiers, France
    • Not yet recruiting
    • Service d'hématologie greffe Hôpital St Louis
    • Contact: Deborah Desmier, MD
    • Principal Investigator: Deborah Desmier, MD
  • Rouen, France
    • Not yet recruiting
    • Département d'hématologie CAC Rouen
    • Contact: Anne-Lise Menard, MD
    • Principal Investigator: Anne-Lise Menard, MD
  • Saint-Étienne, France
    • Not yet recruiting
    • Hématologie clinique Institut de Cancérologie de la Loire
    • Contact: Emmanuelle Tavernier, MD
    • Principal Investigator: Emmanuelle TAVERNIER, MD
  • Toulouse, France
    • Not yet recruiting
    • IUC T - Oncopôle
    • Contact: Anne Huynh, MD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Patient aged 18 or over
• Men and women
• Patients affiliated with a social-security organization
• Patients undergoing a myelo-ablative allo-HSCT for a controlled haematologic malignant disease, with peripheral stem cells, whatever the type of donor (except cord blood)
• Signed and dated informed consent

Exclusion Criteria:

• Status of tumor progression at the time of allo-HSCT
• Inability to understand the protocol (linguistic barrier, cognitive difficulties)
• Medical history of another progressive cancer or occurrence in the 3 previous years (excluding basal cell carcinoma)
• Presence of a simultaneous serious and uncontrolled disease (severe cardiac, renal, hepatic or respiratory failure, severe sepsis)
• Fecal incontinence
• Participation in another clinical trial studying an allograft procedure including the type of graft, the type of immunosuppression, a preventive or a curative treatment of GvHD, or studying the effectiveness of a FMT in another indication.
• Pregnant women
• Patient under guardianship, curatorship or protection of justice

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Group 1: Fecal Microbiota Transplantation (FMT); Patients randomized in the "FMT group" will received FMT. FMT product will be made by the the pharmacy of the Clermont-Ferrand University Hospital from stools of healthy volunteer donors within 6 hours after defecation in order to preserve the viability of the bacteria. The preparation will be standardized: 50g aliquots will be prepared and diluted in 250mL of 0.9% NaCl containing 10% glycerol, until a homogeneous suspension is obtained. The preparation will be rapidly frozen at -80°C until use, with a maximum shelf life of 18 months.	Drug: Fecal Microbiota Transplantation; Patients randomized in the "FMT group" will received FMT within 4 weeks following neutrophils recovery after the allo-HSCT procedure. The stool transplant will be done by enema. The day before FMT, patient will undergo bowel cleansing by ingestion of two liters of polyethylene glycol solution. The day of FMT, a colon cleanse enema will be performed in the morning and FMT will be delivered around two hours after the cleanse enema. This colic preparation is essential to optimize the results of FMT. The enema (50g of stools diluted in 250mL of NaCl 0.9%) will be performed by a qualified member of the study team (nurse) by using a rectal cannula (within 6 hours of thawing). The enema will have to be kept by the patient for as long as possible and at least 30 minutes.
No Intervention: Group 2: no intervention; The comparator group will be constituted by patients randomized in the "no FMT" group. For ethical reasons, these patients will not receive any FMT and therefore no enema or colic preparation. No placebo will be administered. Prophylactic anti-infective treatments can be introduced at any time.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Graft-versus-host disease and Relapse-Free Survival (GRFS) rate after allogeneic hematopoietic stem cell transplantation	GRFS is a composite endpoint of GvHD-free/relapse-free survival in which events include grade II-IV acute GvHD, moderate and severe chronic GvHD, relapse, or death in the first year post-HSCT. GRFS will be measured at one year after allo-HSCT and compared between both groups of patients.	at Day 360 after allogeneic hematopoietic stem cell transplantation

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Overall survival	Overall survival is defined as the time period between the date of randomization and the date of death, regardless of its cause.	At Day 360 and Day 720 after allogeneic hematopoietic stem cell transplantation
Progression-free survival	Progression-free survival is defined as the time period between the date of randomization and the date of disease relapse or progression or death, regardless of its cause.	At Day 360 and Day 720 after allogeneic hematopoietic stem cell transplantation
Haematopoietic reconstitution	Haematopoietic reconstitution is assessed by: 1/ turnaround time of polynuclear neutrophils >0.5.10^9/L (first day within a period of three consecutive days); 2/ spontaneous platelet turnaround time >20.10^9/L (two days with no platelet transfusion within the previous three days); 3/ spontaneous platelet turnaround time >50.10^9/L (two days with no platelet transfusion within the previous three days); 4/ the number of transfusions of red blood cells and platelets between D0 and D100	At the time of haematopoietic reconstitution
Engraftment rates	Engraftment rates are evaluated by a chimerism measure (by molecular biology)	At Day 30, Day 60, Day 90, Day 180, Day 360 and Day 720 after allogeneic hematopoietic stem cell transplantationday
Cumulative incidence of acute GvHD	Acute GvHD severity is defined according to MAGIC criteria. It will be notified by specifying the location (liver, skin, gut …), the severity score (II to IV), the treatment applied and the efficacy of treatment. GvHD occurrence will be notified every week until D30 (minimum) or until hospital discharge, then monthly until D180 and at D270, D360, D540 and D720.	At Day 360 after allogeneic hematopoietic stem cell transplantation
Cumulative incidence of chronic GvHD	Chronic GvHD severity will be defined according to NIHCC criteria. It will be notified by specifying the location (liver, skin, gut …), the severity score (II to IV), the treatment applied and the efficacy of treatment. GvHD occurrence will be notified every week until ungraftment, then monthly until D180 and at D270, D360, D540 and D720.	At Day 720 after allogeneic hematopoietic stem cell transplantation
Transplant-Related Mortality	Transplant-related mortality is defined as death due to causes unrelated to the underlying disease.	At Day 180, Day 360 and Day 720 after allogeneic hematopoietic stem cell transplantation
Cumulative incidence of infections	Infectious complications will be notified every week up to day 30 (minimum) or until hospital discharge, then every month up to D180 and from D270 to D360, according to the existence of a documented bacteraemia, germ resistance, type and number of days of curative antibiotherapy used; the existence of a documented fungal infection and the type and number of days of curative antifungal treatment; the existence of a documented viral infection and the type and number of days of curative antiviral treatment; the need of an intensive care unit transfer due to an infectious complication.	At Day 360 after allogeneic hematopoietic stem cell transplantation
Severe infections description	Severe infections will be defined according to GREFIG score : bactearemia with severe sepsis, complex bactearemia (with deep organ involvement), candidemia (at least one positive blood culture) with sepsis or deep infected site, proven or probable aspergillosis pneumonia, severe varicella-zoster virus infection (involvement of a deep organ or associated coagulopathy), any viral encephalitis, CMV infection with lung or digestive location, Pneumocystis jiroveci pneumonia, toxoplasmosis with involvement of organ or central nervous system, any acute pneumonia with PaO2 less than or equal to 65mmHg, any sepsis requiring transfer to an intensive care unit.	From the day of inclusion to Day 360 after allogeneic hematopoietic stem cell transplantation
Impact of Fecal Microbiota Transplantation (FMT) on multi-resistant bacteria, extended-spectrum beta-lactamases and Clostridium difficile infection	Impact of FMT on multi-resistant bacteria, extended-spectrum beta-lactamases and Clostridium difficile infection will be assessed by evaluation of persistence or disappearance of these pathogenic bacteria after FMT.	At Day 360 after allogeneic hematopoietic stem cell transplantation
Unexpected event description that could be in relation with FMT of Fecal Microbiota Transplantation (FMT)	Each unexpected event that could be in relation with FMT will be notified: abdominal pain, diarrhea, bacterial translocation or any adverse effect attributed to the enema.	From the day of FMT to Day 360 after allogeneic hematopoietic stem cell transplantation
Quality of life assessment	The quality of life will be auto-evaluated by the patients using a validated questionnaire: European Organisation for Research and Treatment of Cancer- Quality of Life Questionnaire-Core 30 (EORTC-QLQ-C30). The QLQ-C30 is composed of both multi-item scales and single-item measures. These include five functional scales, three symptom scales, a global health status / QoL scale, and six single items. Each of the multi-item scales includes a different set of items - no item occurs in more than one scale. All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level. Thus a high score for a functional scale represents a high / healthy level of functioning, a high score for the global health status / QoL represents a high QoL, but a high score for a symptom scale / item represents a high level of symptomatology / problems.	at Day -7, Day 30, Day 90, Day 180, Day 360 and Day 720 after allogeneic hematopoietic stem cell transplantation
Analysis the intestinal microbiota in patients	The intestinal microbiota composition and diversity will be assessed by 16S-rRNA sequencing performed prospectively in all patients with FMT and without FMT.	Before the conditioning regimen, before the FMT and at Day 30, Day 90 and Day 360 after white blood cells recovery
Analysis the intestinal microbiota in stool donnors	The intestinal microbiota composition and diversity will be assessed by 16S-rRNA sequencing performed prospectively in all stool donnors.	At the time of the first stool donnation between Day 7 to Day 55 after the inclusion
Blood collection for a metabolomic study in patients	A blood collection will be set up from blood samples collected on patients from both groups. These samples will be used for a metabolomic study (tryptophan, indoleamine 2,3-dioxygenase, short chain fatty acid, bile acids).	Before the conditioning regimen, before the FMT and at Day 30, Day 90 and Day 360 after white blood cells recovery
Blood collection for an analysis of anti-microbiota IgG and IgA in patients	A blood collection will be set up from blood samples collected on patients from both groups. These samples will be used for an analysis of anti-microbiota IgG and IgA.	Before the conditioning regimen, before the FMT and at Day 30, Day 90 and Day 360 after white blood cells recovery
Blood collection for a metabolomic study in stool donnors	A blood collection will be set up from blood samples collected on stool donnors. These samples will be used for a metabolomic study (tryptophan, indoleamine 2,3-dioxygenase, short chain fatty acid, bile acids).	At the time of the first stool donnation between Day 7 to Day 55 after the inclusion
Blood collection for an analysis of anti-microbiota IgG and IgA in stool donnors	A blood collection will be set up from blood samples collected on stool donnors. These samples will be used for an analysis of anti-microbiota IgG and IgA.	At the time of the first stool donnation between Day 7 to Day 55 after the inclusion
Stool collection for an analysis of the virome in patients	A stool collection will be carried out from stool samples collected on patients from both groups.These samples will be used for an analysis of the virome evolution.	Before the conditioning regimen, before the FMT and at Day 30, Day 90 and Day 360 after white blood cells recovery
Stool collection for an analysis of the virome in stool donnors	A stool collection will be carried out from stool samples collected on stool donnors.These samples will be used for an analysis of the virome evolution.	At the time of the first stool donnation between Day 7 to Day 55 after the inclusion

Collaborators and Investigators

• Sponsor: University Hospital, Clermont-Ferrand
• Collaborators: Ministry of Health, France; French Society of Hematology
• Investigators: Principal Investigator: Jacques-Olivier BAY, MD, PhD, University Hospital, Clermont-Ferrand; Principal Investigator: Stéphanie NGUYEN, MD, PhD, Groupe hospitalier Pitié-Salpêtrière, Paris

Study record dates

Study Major Dates

• Study Start (Actual): December 20, 2022
• Primary Completion (Anticipated): October 1, 2026
• Study Completion (Anticipated): December 1, 2027

Study Registration Dates

• First Submitted: June 1, 2021
• First Submitted That Met QC Criteria: June 15, 2021
• First Posted (Actual): June 23, 2021

Study Record Updates

• Last Update Posted (Actual): March 1, 2023
• Last Update Submitted That Met QC Criteria: February 28, 2023
• Last Verified: October 1, 2022

More Information

Terms related to this study

• Keywords: Fecal Microbiota Transplantation; Intestinal microbiota; Hematologic malignancies; Graft versus Host Disease; Allogeneic hematopoietic stem cell transplantation; Intestinal dysbiosis
• Additional Relevant MeSH Terms: Pathologic Processes; Immune System Diseases; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Immunoproliferative Disorders; Disease; Bone Marrow Diseases; Hematologic Diseases; Leukemia, Lymphoid; Leukemia, B-Cell; Lymphoma; Syndrome; Myelodysplastic Syndromes; Leukemia; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell
• Other Study ID Numbers: PHRC N 2018 BAY; 2020-000673-24 (EudraCT Number)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: Full protocol, participant-level data, statistical codes, trial datasets and analyses will be made available on request from the corresponding author after examining the request.
• IPD Sharing Time Frame: At the end of the study, on request from the corresponding author after examining the request.
• IPD Sharing Access Criteria: On request from the corresponding author after examining the request.
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL; SAP; ICF; ANALYTIC_CODE; CSR

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No